Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review
Cid Ould Ouali,
Nadia Ladjouzi,
Khidher Tamas,
Hendriniaina Raveloson,
Jihene Ben Hassen,
Nesrine El Omeiri,
Georges Zouloumis,
Mohamed Moataz Al Zoabi,
Muneer Asadi,
Aziza Jhouri,
Joël Schlatter
Affiliations
Cid Ould Ouali
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Nadia Ladjouzi
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Khidher Tamas
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Hendriniaina Raveloson
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Jihene Ben Hassen
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Nesrine El Omeiri
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Georges Zouloumis
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Mohamed Moataz Al Zoabi
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Muneer Asadi
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Aziza Jhouri
Pharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
Joël Schlatter
Pharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France
The new coronavirus disease 2019 (COVID-19) could be associated with elevated inflammatory cytokine levels, suggesting the involvement of cytokine release syndrome. This syndrome is characterized by release of interleukin 6 correlated with COVID-19 severity and mortality. Targeting IL-6 with Tocilizumab treatment could be a potential therapeutic option for old patients. We report the case of an 88-year-old man with COVID-19 disease who presented at the admission with anemia, fever, oxygen desaturation (92%), and inflammatory syndrome (C-reactive protein (CRP) at 182.5 mg/L; reference range <5.0 mg/L). After remaining CRP level increase (206.6 mg/L), Tocilizumab administration led to rapid clinical outcome and resolution of his inflammatory syndrome. This case report represents a supplementary data confirming the efficacy and safety of Tocilizumab for COVID-19 in elderly patients.
